Parallel Advisors, LLC Apellis Pharmaceuticals, Inc. Transaction History

Parallel Advisors, LLC

  • $4.34 Billion
  • Q4 2024

A detailed history of Parallel Advisors, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 737 shares of APLS stock, worth $18,535. This represents 0.0% of its overall portfolio holdings.

Number of Shares
737
Previous 1,879 60.78%
Holding current value
$18,535
Previous $54,000 57.41%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 10, 2025
SELL
$26.18 - $35.42 $29,897 - $40,449
-1,142 Reduced 60.78%
737 $23,000
Q3 2024

Nov 13, 2024
BUY
$28.84 - $41.15 $7,210 - $10,287
250 Added 15.35%
1,879 $54,000
Q2 2024

Aug 08, 2024
BUY
$38.07 - $59.71 $3,350 - $5,254
88 Added 5.71%
1,629 $62,000
Q1 2024

May 06, 2024
BUY
$55.39 - $72.47 $2,437 - $3,188
44 Added 2.94%
1,541 $90,000
Q4 2023

Feb 09, 2024
BUY
$37.14 - $64.82 $2,636 - $4,602
71 Added 4.98%
1,497 $89,000
Q3 2023

May 20, 2024
BUY
$23.65 - $89.22 $11,115 - $41,933
470 Added 49.16%
1,426 $54,000
Q3 2023

Nov 13, 2023
BUY
$23.65 - $89.22 $11,115 - $41,933
470 Added 49.16%
1,426 $54,000
Q2 2023

May 20, 2024
BUY
$76.68 - $93.31 $1,073 - $1,306
14 Added 1.49%
956 $87,000
Q2 2023

Aug 04, 2023
BUY
$76.68 - $93.31 $1,073 - $1,306
14 Added 1.49%
956 $87,000
Q1 2023

May 20, 2024
SELL
$46.59 - $66.96 $27,907 - $40,109
-599 Reduced 38.87%
942 $62,000
Q1 2023

Apr 25, 2023
BUY
$46.59 - $66.96 $40,440 - $58,121
868 Added 1172.97%
942 $62,000
Q4 2022

Feb 03, 2023
SELL
$43.24 - $61.04 $302 - $427
-7 Reduced 8.64%
74 $3,000
Q3 2022

Nov 10, 2022
BUY
$44.76 - $69.66 $313 - $487
7 Added 9.46%
81 $6,000
Q2 2022

Aug 01, 2022
SELL
$35.07 - $59.21 $1,963 - $3,315
-56 Reduced 43.08%
74 $3,000
Q1 2022

Apr 28, 2022
SELL
$35.46 - $54.12 $70 - $108
-2 Reduced 1.52%
130 $6,000
Q4 2021

Jan 20, 2022
BUY
$30.74 - $49.16 $2,244 - $3,588
73 Added 123.73%
132 $6,000
Q4 2020

Feb 02, 2021
SELL
$30.79 - $57.2 $1,570 - $2,917
-51 Reduced 46.36%
59 $3,000
Q3 2020

Oct 27, 2020
SELL
$25.89 - $33.65 $1,165 - $1,514
-45 Reduced 29.03%
110 $3,000
Q2 2020

Jul 16, 2020
BUY
$24.8 - $38.49 $3,844 - $5,965
155 New
155 $5,000

Others Institutions Holding APLS

# of Institutions
302
Shares Held
123M
Call Options Held
2.63M
Put Options Held
845K
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $2.76B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email